Preclinical Drug Development: Application Of Advanced Models And Predictive Methods In Safety Assessment

Keywords

Abstract

References

1. [1]ICH Harmonised Guideline. M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. 2009.
2. [2]FDA Guidance for Industry. M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. 2010.
3. [3]Greaves P, Williams A, Eve M. First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov. 2004;3(3):226-36.
4. [4]ICH Harmonised Guideline. S9 nonclinical evaluation for anticancer pharmaceuticals. 2009.
5. [5]OECD. OECD guidelines for the testing of chemicals. Section 4: Health effects. Paris: OECD Publishing; 2022.
6. [6]Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51.
7. [7]Breslin S and O'Driscoll L. Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today. 2013;18(5-6):240-9.
8. [8]Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022;23(8):467-91.
9. [9]Hartung T. Thresholds of toxicological concern setting a threshold for testing where there is little concern. ALTEX. 2017;34(3):331-51.
10. [10]Leist M, Ghallab A, Graepel R, Marchan R, Hassan R, Bennekou SH, et al. Adverse outcome pathways: opportunities, limitations and open questions. Arch Toxicol. 2014;88(11):2053-74.
11. [11]Lancaster MA and Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345(6194):1247125.
12. [12]Qian X, Song H, Ming GL, et al. Brain organoids: advances, applications and challenges. Development. 2019;146(8):dev166074.
13. [13]Clevers H. Modeling development and disease with organoids. Cell. 2016;165(7):1586-97.
14. [14]Di Lullo E and Kriegstein AR. The use of brain organoids to investigate neural development and disease. Nat Rev Neurosci. 2017;18(10):573-84.
15. [15]Agencia SINC. Organoides cerebrales para desvelar los enigmas genéticos del autismo. Available from:https://www.agenciasinc.es/Noticias/Organoides-cerebrales-para-desvelar-los-enigmas-geneticos-del-autismo
16. [16]Cascante A. Tecnología y biología mezcladas para crear un mini cerebro funcional. 2023. Available from: https://www.zonamovilidad.es/tecnologia-biologia-cerebro-humano-organoide-funcional
17. [17]Pamies D, Barreras P, Block K, Makri G, Kumar A, Wiersma D, et al. A human brain microphysiological system derived from induced pluripotent stem cells to study neurological diseases and toxicity. ALTEX. 2017;34(3):362-76.
18. [18]Takebe T and Wells JM. Organoids by design. Science. 2019;364(6444):956-9.
19. [19]Waters MD and Fostel JM. Toxicogenomics and systems toxicology: aims and prospects. Nat Rev Genet. 2004;5(12):936-48.
20. [20]Kawadkar M. Revolutionizing toxicology: organ-on-a-chip insights in a snapshot. Adv Tissue Eng Regen Med Open Access. 2024;10(1):18-20.
21. [21]Han S, Zhang Y, Li X, Wang J, Chen L, Liu H, et al. Integrating a microphysiological system and physiologically based pharmacokinetic modeling to predict human responses to diclofenac. Res Square [Preprint]. 2024.
22. [22]Astashkina AI and Grainger DW. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. Adv Drug Deliv Rev. 2014;69-70:1-18
23. [23]Morizane R. and Bonventre J. V. (2017). Generation of nephron progenitor cells and kidney organoids from human pluripotent stem cells. Nature Protocols, 12(1), 195-207.
24. [24]Edmonds ME, Woodruff TK, Shea LD, et al. Testicular organoid generation and male germline stem cell culture. Methods Cell Biol. 2020;159:217-52.
25. [25]Laronda MM, Rutz AL, Xiao S, Whelan KA, Duncan FE, Roth EW, et al. A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice. Nat Commun. 2017;8:15261.
26. [26]Velasco S, Kedaigle AJ, Simmons SK, Nash A, Rocha M, Quadrato G, et al. Individualbrain organoids reproducibly form cell diversity of the human cerebral cortex. Nature. 2019;570(7762):523-7.
27. [27]Bell CC, Hendriks DFG, Moro SML, Ellis E, Walsh J, Renblom A, et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep. 2016;6:25187.
28. [28]Hofer M and Lutolf MP. Engineering organoids. Nat Rev Mater. 2021;6(5):402-20.
29. [29]Schutgens F and Clevers H. Human organoids: tools for understanding biology and treating diseases. Annu Rev Pathol. 2020;15:211-34.
30. [30]Kojima H and Hirabayashi Y. New approach method for drug discovery and development aimed at regulatory acceptance. Folia Pharmacol Jpn. 2023;158(3):221-5.
31. [31]Sawai T, Hatta T, Fujita M, et al. The ethics of cerebral organoid research. EMBO J. 2022;41(14):e109783.
32. [32]Low LA, Mummery C, Berridge BR, Austin CP, Tagle DA, et al. Organs-on-chips: into the next decade. Nat Rev Drug Discov. 2021;20(5):345-61.
33. [33]Benam KH, Villenave R, Lucchesi C, Varone A, Hubeau C, Lee HH, et al. Small airway-on a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat Methods. 2016;13(2):151-7.
34. [34]Jang KJ, Otieno MA, Ronxhi J, Lim HK, Ewart L, Kodella KR, et al. Reproducing human and cross-species drug toxicities using a liver-chip. Sci Transl Med. 2019;11(517):eaax5516.
35. [35]Freag MS, Namgung B, Reyzelman AM, et al. Human nonalcoholic steatohepatitis on a chip. Hepatol Commun. 2021;5(4):217-33.
36. [36]Weber EJ, Chapron A, Chapron BD, Voellinger JL, Lidberg KA, Yeung CK, et al. Development of a microphysiological model of human kidney proximal tubule function. Kidney Int. 2016;90(3):627-37.
37. [37]Wilmer MJ, Ng CP, Lanz HL, Vulto P, Suter-Dick L, Masereeuw R. Kidney-on-a-chip technology for drug-induced nephrotoxicity screening. Trends Biotechnol. 2016;34(2):156-70.
38. [38]Kasendra M, Tovaglieri A, Sontheimer-Phelps A, Jalili-Firoozinezhad S, Bein A, Chalkiadaki A, et al. Development of a primary human small intestine-on-a-chip using biopsy-derived organoids. Sci Rep. 2018;8:2871.
39. [39]Garcia MI, Smith J, Brown T, et al. Nonclinical human cardiac new approach methodologies (NAMs) predict vanoxerine-induced proarrhythmic potential. J Cardiovasc Dev Dis. 2025;12(8):285.
40. [40]Maschmeyer I, Lorenz AK, Schimek K, Hasenberg T, Ramme AP, Hübner J, et al. A four organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip. 2015;15(12):2688-99.
41. [41]Wikswo JP, Curtis EL, Eagleton ZE, Evans BC, Kole A, Hofmeister LH, et al. Scaling and systems biology for integrating multiple organs-on-a-chip. Lab Chip. 2013;13(18):3496-511.
42. [42]Kimura H, Sakai Y, Fujii T. Organ/body-on-a-chip based on microfluidic technology for drug discovery. Drug Metab Pharmacokinet. 2018;33(1):43-8.
43. [43]Ewart L, Apostolou A, Briggs SA, Carman CV, Chaff JT, Heng AR, et al. Navigating tissue chips from development to dissemination: a pharmaceutical industry perspective. Exp Biol Med (Maywood). 2018;242(16):1579-85.
44. [44]Science in School. Organ-on-a-chip. 2021. Available from: https://scienceinschool.org/es/article/2021/organ-on-chip/
45. [45]Picollet-D'hahan N, Zuchowska A, Lemeunier I, Le Gac S, et al. Multiorgan-on-a-chip: a systemic approach to model and decipher inter-organ communication. Trends Biotechnol. 2021;39(8):788-810.
46. [46]Fowler S, Chen X, Duignan DB, Gupta A, Hariparsad N, Kenny JR, et al. Microphysiological systems for ADME-related applications: current status and recommendations for system development and characterization. Lab Chip. 2020;20(3):446-67.
47. [47]Zhuang X and Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 2016;6(5):430-40.
48. [48]Paini A, Leonard JA, Joossens E, Bessems JGM, Desalegn A, Dorne JLCM, et al. Next generation physiologically based kinetic models. Comput Toxicol. 2019;9:61-72.
49. [49]Hartmanshenn C, Scherholz M, Androulakis IP. Physiologically based pharmacokinetic models: approaches and challenges. Curr Opin Toxicol. 2020;23-24:92-8.
50. [50]Afshari CA, Hamadeh HK, Bushel PR. The evolution of toxicogenomics: a decade of progress. Toxicol Sci. 2011;120(Suppl 1):S225-37.
51. [51]Go YM and Jones DP. Redox biology and toxicology. Chem Res Toxicol. 2017;30(1):1-12.
52. [52]Raies AB and Bajic VB. In silico toxicology: computational methods for the prediction of chemical toxicity. Wiley Interdiscip Rev Comput Mol Sci. 2016;6(2):147-72.
53. [53]Marx U, Akabane T, Andersson TB, Baker E, Beilmann M, Beken S, et al. Biology-inspired microphysiological systems. Trends Pharmacol Sci. 2020;41(6):420-42.
54. [54]Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M, et al. QSAR modeling: where have you been? where are you going to? J Med Chem. 2014;57(12):4977-5010.
55. [55]Wenzel A, Fritsch S, Baumann G, Klingmüller U. Learning relationships between chemical structure and toxicity. PLoS Comput Biol. 2019;15(4):e1006673.
56. [56]Gintant G, Sager PT, Stockbridge N, et al. Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov. 2016;15(7):457-71.
57. [57]Rovida C, Alépée N, Api AM, Basketter DA, Bois FY, Caloni F, et al. Integrated testing strategies (ITS) for safety assessment. ALTEX. 2015;32(1):25-40.

Authors (1)